Linear IgA bullous dermatosis following Oxford AstraZeneca COVID-19 vaccine

A case of linear IgA bullous dermatosis developing 3 days after the second dose of Oxford AstraZeneca COVID-19 vaccine in an adult patient, suggesting a possible causal association. It is worth keeping in mind that COVID-19 vaccination could induce immune-mediated bullous disease in susceptible people.

Automated summary

This case suggests a possible causal association between the COVID-19 vaccine and linear IgA bullous dermatosis, highlighting the importance of monitoring for immune-mediated bullous diseases following vaccination.